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Diabetes, obesity, and cancer affect upward of 15%
of the world’s population. Interestingly, all three dis-
eases juxtapose dysregulated intracellular signaling
with altered metabolic state. Exactly which genetic
factors define stable metabolic set points in vivo
remains poorly understood. Here, we show that
hedgehog signaling rewires cellular metabolism.
We identify a cilium-dependent Smo-Ca2+-Ampk
axis that triggers rapid Warburg-like metabolic re-
programming within minutes of activation and is
required for proper metabolic selectivity and flexi-
bility. We show that Smo modulators can uncouple
the Smo-Ampk axis from canonical signaling and
identify cyclopamine as one of a new class of ‘‘selec-
tive partial agonists,’’ capable of concomitant inhibi-
tion of canonical and activation of noncanonical
hedgehog signaling. Intriguingly, activation of the
Smo-Ampk axis in vivo drives robust insulin-inde-
pendent glucose uptake in muscle and brown
adipose tissue. These data identify multiple nonca-
nonical endpoints that are pivotal for rational design
of hedgehog modulators and provide a new thera-
peutic avenue for obesity and diabetes.414 Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc.INTRODUCTION
Hedgehog was initially described as a morphogen defining
body patterning (Nu¨sslein-Volhard and Wieschaus, 1980). In
mammals, ligand binding to the inhibitory cell surface receptor
Patched (Ptch) permits Smoothened (Smo) translocation to the
tip of the cilium and liberates zinc finger family transcription
factors Gli1, Gli2, and Gli3 from proteasomal degradation and
inhibitory tethering leading to activation of Gli target genes (Hui
and Angers, 2011; Ingham et al., 2011; Riobo and Manning,
2007; Rohatgi and Scott, 2007; Ruiz i Altaba et al., 2007). Three
highly homologous mammalian ligands exist for Drosophila
hedgehog, namely Desert, Indian, and Sonic hedgehogs (Dhh,
Ihh, and Shh, respectively). Whereas the majority of hedgehog-
induced biological effects are thought to result from tran-
scriptional regulation, several Gli-independent, noncanonical
modules have also been reported (Riobo andManning, 2007; Te-
glund and Toftga˚rd, 2010). Shh, for instance, rapidly stimulates
Src family kinases to spatially direct axonal outgrowth in vitro
(Yam et al., 2009), and all three hedgehog ligands have been
shown to promote cytoskeletal rearrangement via a Smo-Gi-
RhoA axis in endothelial cells (Chinchilla et al., 2010). Further-
more, coupling of hedgehog to Rho small GTPases has been
linked to the activation of fibroblast migration (Polizio et al.,
2011). More recently, Shh has been shown to boost Ca2+ and
IP3 transients in spinal neurons through a G-protein- and Ca
2+-
dependent pathway (Belgacem and Borodinsky, 2011).
Hedgehog activation impacts dozens of cellular processes,
including stem cell renewal, lineage decision, cell-cycle regula-
tion, migration, and mitogenic signaling (Hui and Angers, 2011;
Ingham et al., 2011; Rohatgi and Scott, 2007; Ruiz i Altaba
et al., 2007; Teglund and Toftga˚rd, 2010). Accordingly, activating
mutations in hedgehog pathway members have been causally
implicated in a number of disparate cancers, including medullo-
blastoma, basal cell carcinoma, pancreatic cancers, and can-
cers of the intestinal tract (Ng and Curran, 2011; Teglund and
Toftga˚rd, 2010). Also, hedgehog signaling specifically blocks
white, but not brown, adipogenesis (Pospisilik et al., 2010; Suh
et al., 2006). This biological effect is sensitive to inflammatory
state (Todoric et al., 2011) and represents one of the few
known signaling nodes that are capable of differentially regu-
lating brown versus white adipocyte differentiation (Lowe et al.,
2011). All three factors—inflammation, adipocyte turnover, and
adipose subtype distribution—show substantial imbalance in
obesity and represent targets for therapeutic intervention
(Lumeng and Saltiel, 2011; Whittle et al., 2011). Inhibitors of
hedgehog signaling from at least seven pharmaceutical com-
panies are currently in clinical trials (Ng and Curran, 2011).
Intriguingly, despite their advanced development, a universal
mechanism underlying hedgehog inhibitor efficacy is lacking.
Specifically, potency of canonical hedgehog pathway inhibition
does not match potency of inhibition of cancer growth (Yauch
et al., 2008). One proposed mechanism to explain these anom-
alies has been indirect cancer modulation through paracrine or
mesenchyme-tumor interaction (Chen et al., 2011; Chinchilla
et al., 2010; Theunissen and de Sauvage, 2009; Yauch et al.,
2008).
In the current study, we show that hedgehog stimulates meta-
bolic reprogramming toward aWarburg-like glycolytic state. The
effect, mediated by a rapid noncanonical Smo-Ca2+-Ampk
signaling arm effects robust glucose uptake in vivo in the mouse
and in human myocytes and surprisingly is also induced by
several canonical hedgehog inhibitors. The results provide
critical insights into the substantial hedgehog inhibitor side
effects in humans and into the complexity of hedgehog signaling
itself, and they raise new therapeutic strategies for obesity and
type-1 diabetes.
RESULTS
Hedgehog Reprograms Energy Metabolism
Hedgehog signaling regulates multiple cellular processes, in-
cluding twowith finely tunedmetabolic programs, namely cancer
and adipose tissue development. We asked whether hedgehog
might determine metabolic state. We chose 3T3-L1 adipocytes
as a model because they exhibit some of the best characterized
metabolic regulatory circuits and they respond fully to hedgehog
(Pospisilik et al., 2010). Intriguingly, stimulation of mature 3T3-L1
adipocytes with smoothened agonist (SAG) (Chen et al., 2002b),
a small molecule activator of Smo, led to acidification of culture
media within 24 hr (Figure 1A). Quantitation revealed increased
extracellular acidification (ECAR) and reduced oxygen consump-
tion (OCR) rates upon SAG stimulation (Figure 1B), findings that
are consistent with reduced glucose and increased lactate levels
in the culture medium (Figure 1C). Further, levels of the oxidizedredox equivalents NAD+ and NADP+ (Figure 1D) were elevated,
indicating substrate rerouting away from energy production.
Importantly, reduced forms of the redox equivalents NADH and
NADPH remained unchanged, as did ATP levels, yielding an
overall increase in redox ratios (Figure 1E and Figures S1A and
S1B available online). This metabolic reset was reminiscent
in many ways to the Warburg effect observed in cancer and
to the metabolic rearrangements that characterize stem cell
renewal and immune cell activation (Hsu and Sabatini, 2008;
Shi et al., 2011; Vander Heiden et al., 2009). Importantly, no
evidence of proliferation was found in these terminally differen-
tiated, growth-arrested cells. Pathway stimulation using the
endogenous ligand Shh recapitulated all key aspects of the
metabolic phenotype (Figures 1F–1H and S1C), and, whereas
wild-type primarymouse embryonic fibroblasts (MEFs) exhibited
significant SAG-stimulated metabolic shifts, Smo/MEFs (Var-
josalo et al., 2006) showed none (Figures 1I–1K), thus ruling out
potential chemical artifacts. Importantly, these findings were
recapitulated in the 3T3-L1 system upon Smo knockdown
(FiguresS1D–S1F). Thus, hedgehog signaling reprogramsadipo-
cyte metabolism toward aerobic glycolysis.
Hedgehog Triggers Rapid Metabolic Rewiring via Ampk
Next, we performed a time course of glucose removal from and
lactate accumulation into 3T3-L1 culture supernatants. Surpris-
ingly, marked glucose removal and lactate generation were
observed within minutes of SAG addition (Figures 2A and 2B),
a finding completely inconsistent with transcriptionally driven
canonical hedgehog signaling (Figure S2A). To understand how
Smo activation could lead to such rapid metabolic reprogram-
ming, we performed a phosphoproteomic survey of the acute
hedgehog signaling response. Two-dimensional gel electropho-
resis was used to resolve phospho-enriched lysates from differ-
entiated 3T3-L1 adipocytes treated for 10 min with or without
SAG (Figure 2C). Of the 632 spots that were consistently de-
tected in three independent experiments, 55 spots comprising
39 specific phosphoproteins showed reproducible differential
regulation > 1.5-fold (Table S1). This data set presents an unbi-
ased snapshot of rapid noncanonical hedgehog signaling and
identifies numerous downstream signaling activities not previ-
ously associatedwith hedgehog. Intriguingly, in aKEGGpathway
analysis, all significantly enriched gene sets except one consti-
tuted compartments of primary energy metabolism, including
glucose, ketone body, fatty acid, pyruvate, and ketogenic amino
acid metabolism, as well as the TCA cycle (Figure 2D and Table
S2). Numerous key regulators of glucose and energymetabolism
were identified, including acetyl-CoA acetyltransferase (Acat1),
glyceraldehyde-3-phosphate dehydrogenase (Gapdh), transal-
dolase 1 (Taldo1), hormone-sensitive lipase (Lipe), phosphoglyc-
erate mutase (Pgam1), glycogen synthase (Gys), and pyruvate
dehydrogenase alpha 1 (Pdha1) (Figure 2E), indicating that
a complex metabolic signaling network exists that is rapidly
accessible to Smoothened. Of interest, the only nonmetabolic
pathway enriched in our analysis was the proteasome, a well-
known and integral component of canonical hedgehog signaling
(Hui and Angers, 2011; Teglund and Toftga˚rd, 2010). Thus,
hedgehog rapidly signals to the machinery of primary energy
metabolism.Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc. 415
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Figure 1. Hedgehog Reprograms Adipocyte Metabolism
(A–E) Differentiated 3T3-L1 adipocytes treated with SAG (200 nM) acidify growthmedium (A); display reduced O2 consumption (OCR) and increased extracellular
acidification (ECAR) (B); utilize more glucose and produce more lactate (C); and show increased NAD+, NADP+ (D) and their ratios within 24 hr of treatment (E).
(F–H) Similarly, treatment with Sonic hedgehog (Shh) increased glucose consumption (F), lactate production (G), and NAD+/NADH ratio (H).
(I–K) Unlike wild-type (WT) MEFs, Smo/MEFs are not responsive to SAG in terms of glucose consumption (I), lactate production (J), or change in NAD+/NADH
ratio (K).
Results are mean ± SEM. n = 4–6 independent experiments. *p < 0.05 compared to vehicle-treated samples. See also Figure S1.To further characterize the hedgehog-driven metabolic phe-
notype, we performed western blot time course analysis of
Pdha1, AMP-activated protein kinase (Ampk), and pyruvate
kinase M1/M2 (Pkm2) phosphorylation events. All three proteins
have key roles in deciding glycolytic substrate fate and anabolic-
to-catabolic transitions and have been implicated in the regu-
lation of the Warburg effect and cancer cell growth (Hitosugi416 Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc.et al., 2009; Jeon et al., 2012; Vander Heiden et al., 2009). Intrigu-
ingly, robust phosphorylation signals were observed from all
three proteins within 2 min of either SAG (Figure 2F) or Shh (Fig-
ure S2B), modifications that are consistent with enhanced
glycolysis.
Could Ampk, Pdha1, and Pkm2 be responsible for the
observed metabolic phenotype? shRNA knockdown of Ampk
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Figure 2. Hedgehog Triggers Rapid Metabolic Rewiring via Ampk
(A and B) SAG-treated 3T3-L1 adipocytes increase glucose consumption (A) and lactate production (B) within minutes.
(C) Phospho-2D-gel highlighting spots changed within 10 min of SAG addition.
(D) KEGG pathway analysis of differentially regulated phosphoproteins.
(E) Two significantly phosphorylated spots corresponding to Pdha1.
(F) Western blot time course of SAG-induced protein phosphorylation in 3T3-L1 adipocytes.
(G–K) Ampk and Pkm2 knockdown abrogates SAG-induced glucose disposal (G), lactate production (H), and elevation in NAD+/NADH ratio (I). Glut4 knockdown
blunts SAG-induced glucose uptake (J) and lactate production (K).
(L) A plasmid-encoded FRET based assay in HEK293 cells shows rapid induction of AMPK activity upon SAG treatment.
Results are mean ± SEM. n = 4–6 independent experiments. *p < 0.05 compared to vehicle-treated samples (A and B) or scrambled shRNA-transfected cells
(G–K). See also Figure S2.in 3T3-L1 adipocytes (Figure S2C) completely abolished SAG-
stimulated disruption of redox balance, extracellular glucose/
lactate levels, and OCR/ECAR flux levels (Figures 2G, 2H, and
S2D). Similarly, preincubation of cells with compound C, an
inhibitor of Ampk activity, abrogated detectable metabolic rewir-
ing effects following SAG stimulation in both fully differentiated
3T3-L1 adipocytes (Figures S2D–S2F) and MEFs (Figures S2G
and S2H). Importantly, OCR/ECAR measures confirmed that
neither Ampk knockdown nor Ampk inhibition alone reduced
metabolic rate. Knockdown of Pdha1 on the other hand (Fig-
ure S2I), a genetic mimic of its phosphorylation-mediated inhibi-
tion, showed no apparent effect on SAG-induced glucose
uptake (Figure 2G) but substantially enhanced cellular lactate
release (Figure 2H) and redox rebalancing (Figure 2I). Disruption
of Pkm2 (Figure S2I), interestingly, blunted any sign of a SAG-inducible glucose/lactate response and increased basal lactate
accumulation (Figures 2G and 2H). Collectively, these results
suggest that Ampk and Pkm2 mediate SAG-induced glucose
uptake, whereas Pkm2 and Pdha1 focus substrate flux toward
lactate. In keeping with a largely Ampk-driven process, SAG-
induced glucose uptake was Glut4 dependent, but neither
Glut1 dependent nor insulin receptor dependent (Figures 2J,
2K, and S2I). Thus, Smo activation drives Ampk/Pkm2/Pdha1-
dependent metabolic rewiring.
To better define the kinetics of the noncanonical response, we
used AMPKAR, a Foerster resonance energy transfer (FRET)
probe for AMPK activity (Tsou et al., 2011). Because transfection
and FRET signal detection in mature adipocytes is poor, we
used HEK293 cells, which have previously been used for
high-throughput hedgehog screening (Roudaut et al., 2011).Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc. 417
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Figure 3. A Smo-Camkk2-Ampk Axis
(A–C) Lkb1 and Camkk2 knockdown abrogates SAG-induced glucose disposal (A), lactate production (B), and NAD+/NADH elevation (C) in 3T3-L1 adipocytes.
(D) SAG-treated adipocytes show a rapid and robust calcium response completely blunted by the extracellular calcium chelator EGTA (1 mM).
(E) SAG-induced AMPK activity in AMPK-AR reporter expressing HEK293 cells is inhibited by both Nifedipine and Ptx.
(F–H) Nifedipine (20 mM) or Ptx (100 ng/ml) treated 3T3-L1 adipocytes are refractory to SAG-induced glucose disposal (F), lactate production (G), andNAD+/NADH
elevation (H).
Results are mean ± SEM. n = 4–6 independent experiments. *p < 0.05 compared to scrambled shRNA-transfected cells (A–C) or vehicle-treated samples (F–H).
See also Figure S3.Intriguingly, addition of SAG to AMPKAR-expressing HEK293
cells revealed rapid and sustained AMPK-FRET signals detect-
able within 20 s of SAG addition (Figure 2L). Thus, hedgehog
stimulates rapid activation of AMPK in human and mouse cells
and across disparate cell types.
A Smo-Camkk2/Lkb1-Ampk Axis
Though predominantly studied as an activator of Gli-dependent
transcriptional regulation over hours or days, Smo is a class F
G-protein-coupled receptor (Ogden et al., 2008; Polizio et al.,
2011), a class of proteins that effect rapid G-protein-coupled
second messenger signals. Ampk is principally stimulated by
increased AMP/ATP ratio and by the upstream kinases serine/
threonine-protein kinase 11 (Lkb1) and calcium/calmodulin-
dependent protein kinase kinase 2 (Camkk2) (Canto´ and Auwerx,
2011; Hardie, 2011). Using GC/MS, no marked dysregulation in
AMP, ADP, or ATP was observed (Figure S3A), indicating normal
AMP-to-ATP balance. Knockdown of either Lkb1 or Camkk2
(Figures S3B–S3D), however, resulted in near-complete abroga-
tion of SAG-stimulated metabolic sequelae (Figures 3A–3C and
S3E), suggesting that both proteins couple Smo to Ampk. Impor-
tantly, though resistant to Smo-dependent metabolic rewiring,
both Lkb1 and Camkk2 knockdown adipocytes responded fully
to AICAR (Figures S3F–S3H), indicating that Ampk signaling in
these cells remained intact.418 Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc.In line with a key role for Camkk2, SAG stimulation of adipo-
cytes preloaded with the Ca2+-sensitive fluorophore Fluoforte-
AM revealed a Ca2+ response that is more rapid and intense
than a standard 1 mM ionomycin stimulation (Figure 3D). The
same was true for the endogenous ligand Shh (Figure S3I).
Administration of the extracellular calcium chelator EGTA under
the same conditions completely abrogated SAG- and Shh-
induced responses, indicating that Smo activation promotes
opening of plasma membrane Ca2+ channels rather than mobi-
lizing of intracellular stores (Figures 3D and S3I). Importantly,
the L-type calcium channel blocker Nifedipine markedly blunted
both Ampk activity (Figures 3E, S3J, and S3K) and the observed
metabolic phenotype (Figures 3F–3H). Moreover, Pertussis toxin
(Ptx), a potent inhibitor of receptor-to-Gai G protein coupling,
blunted Ampk activation and metabolic rerouting (Figures 3E–
3H). Thus, a rapid Ca2+- and Gai-dependent noncanonical
Smo-Ampk signaling axis rewires metabolism.
Noncanonical Rewiring of Metabolism Is Primary Cilium
Dependent
Canonical hedgehog signaling requires Smo translocation to the
primary cilium (Corbit et al., 2005; Rohatgi et al., 2007, 2009;
Wang et al., 2009). We used cilia-deficient Ift88/ and Kif3a/
MEFs and their respective control cell lines to probe the cilia
dependence of our system. Intraflagellar transport protein 88
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Figure 4. Noncanonical Rewiring of Metabolism Is Primary Cilium Dependent
(A–D) MEFs derived from either Ift88 or Kif3a knockout mice show no SAG-induced glucose disposal (A), lactate production (B), or Ampk activation (D) despite an
intact Ca2+ response (C).
(E and F) Smo knockdown abrogates SAG-induced glucose disposal (E) and lactate production (F) in 3T3-L1 adipocytes, effects that are rescued by the
reintroduction of wild-type Smo, but not SmoM2 and Smo-CLD mutants.
(G and H) MEFs derived from Ptch/mice show increased basal glucose disposal (G) and lactate production (H) with no further SAG response. Responsiveness
is restored by chronic treatment with 100 nM SANT-1.
(I) Coimmunoprecipitation analysis of the Smo-Lkb1-Ampk axis.
Results are mean ± SEM. n = 4–6 independent experiments. *p < 0.05 compared to vehicle-treated samples (A–H). xp < 0.05 compared to Smo-KD (E and F) or
Ptch/ cells (G and H). See also Figure S4.(Ift88) and kinesin family member 3A (Kif3a) are required for
proper ciliogenesis, and their loss results in lack of canonical
hedgehog signaling competency and of a functional primary
cilium. Strikingly, whereas control MEFs showed full noncanon-
ical responses to SAG induction, glucose uptake and lactate
production were severely blunted in the mutant lines (Figures
4A and 4B). Importantly, both mutant cell lines exhibited a signif-
icant Ca2+ response to SAG (Figure 4C), but neither exhibited any
sign of Ampk activation by in-cell western blot (Figures 4D and
S4A), indicating that the cilium is necessary to couple Smo-
induction to Ampk activity. Of note, both lines mounted signifi-
cant metabolic responses to AICAR, indicating uncompromised
Ampk and downstream signaling (Figures S4B–S4D). Thus, the
Smo-Ampk response is dependent on the primary cilium.
To corroborate these findings in the adipocyte system, we
tested the ability of several Smo variants to rescue the stable
loss of function in our Smo knockdown 3T3-L1 cells (Figures
4E and 4F). As expected, wild-type Smo-GFP rescued nonca-
nonical signaling competency in the mature knockdown adipo-
cytes. However, transfection with a cilia localization-deficient
Smo mutant (Smo-CLD) was completely incapable of restoring
responsiveness (Figures 4E, 4F, and S4E). This variant harbors
a mutation in two amino acids that are necessary for Smo ciliary
translocation (Corbit et al., 2005). Surprisingly, reconstitution
with the constitutively active SmoM2mutant also failed to rescue
metabolic responsiveness to SAG (Figures 4E, 4F and S4E). Of
note though, SmoM2-reconstituted 3T3-L1 cells did exhibit a
moderate increase in glucose uptake and lactate accumulation
in the basal state. Knowing that canonical activation requiresa second step of Smo translocation from the base to the tip of
the cilium and that SmoM2 accumulates toward the tip (Han
et al., 2008), these findings suggested that the base of the cilium
could be critical in linking Smo induction to Ampk activation. This
interpretation is consistent with the observations that Ptch/
MEFs (constitutively active canonical signaling) exhibit meta-
bolic rewiring in the basal state and show a lack of responsive-
ness to SAG that can be reversed by long-term treatment with
the Ampk blocker compound C. Also, both the basal hyper-
activation and the lack-of-responsiveness phenotypes can be
rescued by long-term preincubation with SANT-1 (Figures 4G
and 4H), which blocks Smo translocation to the cilium base.
Boehlke et al. recently reported a cilium-based system in
kidney epithelial cells coupling mechanical sensation of fluid
flow to cell size regulation via basal-body-restricted Lkb1 and
Ampk (Boehlke et al., 2010). We used coimmunoprecipitation
to test whether an analogous system might be at play here.
Importantly, Lkb1 and Ampk enriched in the g-tubulin immuno-
precipitation of mature 3T3-L1 cells (Figure 4I, third column),
indicating the presence of both proteins at the basal body. Simi-
larly, we observed Lkb1 and Ampk signals pulled down by acet-
ylated a-tubulin (Figure 4I, second column), indicating their pres-
ence in the cilium. Critically, upon SAG activation, we observed:
(1) robust enrichment of P-Ampk with g-tubulin pull-down, iden-
tifying a spatial node for noncanonical signaling at the basal body
(Figure 4I, third column, top), (2) depletion of Lkb1 from the acet-
ylated a-tubulin compartment, and (3) apparent accumulation of
Lkb1 at g-tubulin. Thus, noncanonical Smo signaling to Ampk
appears compartmentalized at the basal body.Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc. 419
05
10
15
*
+ 
Nif
ed
ipi
ne
+ 
Ptx
+ 
Co
m
po
un
d CCtr
l
Cy
c
La
ct
at
e 
(m
M
)
15
20
25
30
*
+ 
Nif
ed
ipi
ne
+ 
Ptx
+ 
Co
m
po
un
d CCtr
l
Cy
c
G
lu
co
se
 
(m
M
)
50 1000
2
4
6
0
Ctrl
Cyc
Cyc/EGTA
Cyc/Ptx
Time (s)
ΔR
FU
 
(x1
00
,0
00
)
0
2
4
6
8
10
*
+ 
Nif
ed
ipi
ne
+ 
Ptx
+ 
Co
m
po
un
d CCtr
l
Cy
c
NA
D+
/N
AD
H 
(A
U)
A B C D
E F G
JH
0
2
4
6
8
10 *
Ctrl
Cyc
NA
D+
/N
AD
H 
(A
U)
0 15 30 45 60
50
100
150
200
250
300
HBS
Cyc
*
*
Time (min)
G
lu
co
se
 
(m
g/
dl
)
I
-90 0 30 60
0
20
40
60
80 HBS
Cyc
*
Time (min)
G
IR
 
(m
g/
kg
.
m
in
)
15
20
25
30 CtrlCyc
*
G
lu
co
se
 (m
M
)
0
5
10
15
Ctrl
Cyc
*
La
ct
at
e 
(m
M
)
0 400 800
0
2
4
Ctrl
Cyc
Cyc/Nife
Cyc/Ptx
Time (s)
ΔF
RE
T 
RF
U 
(x1
00
0)
K L
Sc
r
Sm
o-
sh
15
20
25
30 Ctrl
*
Cyc
G
lu
co
se
 
(m
M
)
Sc
r
Sm
o-
sh
0
2
4
6
8 Ctrl
*
Cyc
La
ct
at
e 
(m
M
)
Figure 5. Smo-Ampk-Selective Partial Ago-
nism Stimulates Glucose Uptake In Vivo
(A–C) Cyclopamine (100 nM) induces metabolic
reprogramming in differentiated 3T3-L1 adipo-
cytes increasing glucose consumption (A), lactate
production (B), and NAD+/NADH (C).
(D) Cyclopamine elicits a rapid EGTA-sensitive
Ca2+ response.
(E) AMPK-AR-expressing HEK293 cells show
rapid induction of AMPK activity upon cyclop-
amine treatment, an effect that is blunted by both
Nifedipine and Ptx.
(F–H) Cyclopamine-induced glucose consumption
(F), lactate production (G), and elevation of NAD+/
NADH (H) are also abrogated by Nifedipine, Ptx,
and compound C.
(I and J) Smo knockdown 3T3-L1 adipocytes show
no sign of cyclopamine-induced glucose disposal
(I) and lactate production (J).
(K) C57BL/6J mice display improved glucose
tolerance (n = 12) when pretreated with cyclop-
amine (10 mg/kg, i.p.; n = 12) relative to vehicle
alone (HBS).
(L) Increased glucose infusion rate (GIR) during
glycemic-insulinemic clamps (n = 6–10).
Results represent mean ± SEM. n = 4–6 indepen-
dent experiments in vitro. *p < 0.05 compared to
vehicle-treated samples. See also Figure S5.Selective Partial Agonism of Metabolic Rewiring In Vitro
and In Vivo
Numerous inhibitors of canonical hedgehog signaling are in
clinical trials for their anticancer potential (Ng and Curran,
2011). To tease apart the relative contributions of canonical
Gli-dependent and noncanonical Ampk-dependent signaling,
we began to test well-characterized hedgehog antagonists for
their potential to block the identified rapid metabolic response.
Surprisingly, when adding the classic hedgehog antagonist cy-
clopamine (Chen et al., 2002a), initially as a negative control,
we observed rapid and robust metabolic reprogramming analo-
gous to that induced by SAG (Figures 5A–5C). These effects
were observed at 100 nM, where cyclopamine binds efficiently
to Smo but is incapable of displacing SAG from their shared
binding site to block canonical signaling (Chen et al., 2002a,420 Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc.2002b). Importantly, cyclopamine is
known to cause Smo translocation to
the basal body of the cilium at these
concentrations. Further, cyclopamine
induced rapid and robust Ca2+ and
AMPKAR responses sensitive to both
extracellular EGTA and Ptx (Figures 5D
and 5E), suggesting that SAG and cyclop-
amine induce a common noncanonical
signal. Critically, cyclopamine-dependent
glucose uptake, lactate production, and
redox rebalancing were also all efficiently
counteracted by addition of Nifedipine,
Ptx, or the Ampk inhibitor compound C
(Figures 5F–5H) and via knockdown of
Smo in the 3T3-L1 system (Figures 5Iand 5J). Thus, (1) Smo modulators can activate noncanonical
signaling independently of the canonical arm, (2) canonical and
noncanonical signaling arms can be uncoupled via the SAG/cy-
clopamine binding site of Smo, and (3) cyclopamine is a potent
selective partial agonist of the noncanonical pathway.
Of chief importance, these findings provided us with a tool
to probe the relevance of the noncanonical axis in vivo. To test
whether Smo-selective partial agonism could boost metabolism
in vivo, we performed oral glucose tolerance tests (OGTT) on
wild-typeC57BL/6Jmice in the presence or absence of acute cy-
clopamine pretreatment. Remarkably, mice receiving 10 mg/kg
cyclopamine 15 min prior to testing displayed a moderate but
significant improvement in glucose tolerance (Figure 5K). Of
note, neither basal- nor glucose-stimulated insulin secretion ap-
peared affected by the pretreatment (Figure S5A). Because
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Figure 6. Insulin-Independent Glucose Uptake in Muscle and Brown Fat
(A) Glucose tracers revealed that cyclopamine enhances glucose uptake in BAT, EDL, and Soleus muscles (EP, epididymal adipose; BAT, brown adipose tissue;
VL, vas lateralis; EDL, extensor digitorum longus; Sol, soleus).
(B–D) Whereas C2C12 myotubes exhibit only increased glucose disposal, primary brown adipocytes (pBAT) show increased glucose consumption (B), lactate
production (C), and elevation of NAD+/NADH (D) upon cyclopamine treatment. The chemical Ampk agonist AICAR (0.5 mM) only partially recapitulates the
phenotypes.
(E) Western blot of cyclopamine-induced Ampk phosphorylation in pBAT and C2C12 myotubes.
(F and G) Cyclopamine treatment (10 mg/kg) induces glucose clearance and elevation in body temperature (n = 6–26) in insulin-deficient STZ-treated C57BL/
6J mice.
Results are mean ± SEM. n = 4–6 independent experiments. *p < 0.05 compared to vehicle-treated samples. See also Figure S6.insulin is known to counteract Ampk activity, we reasoned that an
acute insulin response might be masking the full potential of the
response. We therefore examined the response in hypergly-
cemic-insulinemic clamps exploiting continuous somatostatin
infusion to suppress acute insulin responses. Impressively, under
these conditions, cyclopamine infusion elicited robust glucose
uptake (glucose infusion rate) within 10–20 min of stimulation
(Figure 5L). Thus, Smo-selective partial agonism induces meta-
bolic rewiring and acute glucose uptake in vivo.
Selective Partial Agonism Specifically Activates Muscle
and Brown Fat
In addition, the clamp studies were designed to trace tissue-
specific glucose uptake via introduction of a nonmetabolizable
2-deoxyglucose radiolabel. Intriguingly, rather than the antici-
pated white adipose tissue (WAT) glucose uptake, brown adi-
pose tissue (BAT) and muscles of multiple fiber types (extensor
digitorum longus, EDL, glycolytic; and soleus, Sol, oxidative)
exhibited the dominant cyclopamine-induced glucose uptake
responses in vivo (Figure 6A). To explore the cell autonomy of
this surprising finding, we stimulated C2C12 myotubes and
differentiated primary brown adipocytes (pBAT) with cyclop-
amine and measured glucose, lactate, and NAD+/NADHendpoints as before. In keeping with the clamp results, both
C2C12 and pBAT cells exhibited robust glucose uptake within
10min of cyclopamine stimulation (Figure 6B). Brown adipocytes
produced significant increases in lactate and NAD+/NADH,
whereas the myotubes, whose 10-fold lower lactate release
rates suggest very high oxidative capacity, resisted both down-
stream metabolic sequelae (Figures 6C and 6D). These findings
suggest that the exact metabolic end state resulting from Smo
stimulation depends on the machinery of the tissue type in ques-
tion. Importantly, we observed prominent P-Ampk responses to
cyclopamine in both cell models (Figure 6E). Equally important,
all key endpoints, including in vivo glycemic-insulinemic clamps,
were recapitulated for SAG (Figure S6), corroborating the selec-
tivity of cyclopamine-induced metabolic rewiring. Thus, selec-
tive partial agonism of the Smo-Ampk axis stimulates muscle
and brown fat glucose uptake in mice.
These findings, observed under somatostatin infused condi-
tions, raised the intriguing question of whether the system might
be effective even in the absence of insulin. To test this hypoth-
esis, we treated mice with high-dose streptozotocin (STZ) to
selectively neutralize insulin secretory capacity and generate
a type-1-diabetes-like state. Remarkably, despite a complete
lack of circulating insulin, STZ-treated mice showed significantCell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc. 421
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Figure 7. Smo Controls Metabolic Flexibility and Skeletal Muscle Contraction
(A and B) Smo knockdown increases basal glucose consumption in adipocytes (A) and decreases lactate production in C2C12 cells (B). Both effects are rescued
by the reintroduction of wild-type Smo (A and B).
(C and D) Smo knockdown 3T3-L1 adipocytes exhibit increased metabolic rate (C) and complete lack of glycolytic flexibility upon glucose exposure (D).
(E) Smo knockdown adipocytes show increased metabolism of a broad range of carbon substrates.
(F) Assessment of a panel of Smo modulators revealed tight correlation between induction of a Ca2+ response and contraction and largely uncoupled canonical
(red circles = IC50; green open circles = EC50 Gli induction in Shh-Light2 cells) and noncanonical (green solid circles = EC50 glucose uptake) responses.
(G) Dose-response curves for all compounds inducing glucose uptake.
(H) SAG, cyclopamine, and GDC-0449 induce glucose disposal in primary human myocytes.
Results are mean ± SEM. n = 4–6 independent experiments in vitro. *p < 0.05 compared to vehicle-treated samples. See also Figure S7.and robust glucose clearance within 30 min of cyclopamine
injection (Figure 6F). Further, in direct support of an endogenous
glucose fate including brown adipose tissue, cyclopamine
increased core body temperature 1.0C in the same mice
over a 1 hr period (Figure 6G), suggesting that selective partial
agonism of the Smo-Ampk axis activates thermogenesis in vivo.
Thus, Smo-selective partial agonism induces insulin-indepen-
dent and tissue-selective metabolic rewiring in vivo.
Smo Determines Metabolic Tone, Specificity, and
Flexibility
A number of studies indicate that Smo itself may have endoge-
nous ligands, including two oxysterols 20(s)-OHC and 25-OHC422 Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc.(Corcoran and Scott, 2006; Nachtergaele et al., 2012). Given
the potent gluco-regulatory effects of SAG and cyclopamine,
we revisited our in vitro system to ask whether endogenous
Smo signaling might regulate metabolism. Indeed, Smo knock-
down reduced the anaerobic-to-aerobic ratio (lactate genera-
tion/glucose uptake) in both 3T3-L1 and C2C12 cells, manifest
as either an increase in glucose uptake (3T3-L1) or a reduction
in lactate generation (C2C12) (Figures 7A and 7B). Thus, Smo
appears to modulate metabolic tone independently of exoge-
nous ligand stimulation.
Because Smo knockdown myocytes exhibited significant hy-
percontractility to even minor perturbations, we moved forward
with Smo knockdown 3T3-L1 cells. Intriguingly, despite a high
metabolic rate, Smo knockdown cells were incapable of mount-
ing a substantial switch to glucose utilization when shifted from
no-glucose to high-glucose medium, responding with a 5-fold
smaller OCR burst than control cells (Figures 7C, 7D, and
S7A). Probing further, we used a panel of 180 different carbon
and nitrogen sources to fingerprint Smo knockdown cells meta-
bolically. The test, performed in fuel-depleted medium, mea-
sures substrate utilization for a spectrum of fuel sources one
substrate at a time. Intriguingly, Smo knockdown 3T3-L1 adipo-
cytes exhibited increased fuel utilization for the majority of
substrates tested, including a remarkable 29 substrates com-
pletely unprocessed in control adipocytes (Figure 7E). Removal
of Smo appeared to short-circuit cell type restriction of fuel
use, leaving cells able to metabolize a much wider substrate
repertoire. Thus, Smo regulates metabolic flux, flexibility, and
substrate specificity.
Noncanonical Signaling, Metabolism, and Side Effects
This year, the FDA approved the first hedgehog inhibitor, Vismo-
degib (GDC-0449), for cancer therapy use in humans. Clinical
data are currently available for five hedgehog antagonists:
GDC-0449, LDE-225, XL-139, IPI-926, and PF-0449913 (Li
et al., 2012; Lin and Matsui, 2012; Low and de Sauvage, 2010;
Von Hoff et al., 2009). Unfortunately, the first reports indicate
side effects so severe that dropout rates have exceeded
a discouraging 50% (Sekulic et al., 2012; Tang et al., 2012).
Intriguingly, the physiological effects of our key noncanonical
endpoints are highly consistent with the two major reported
side effects: weight loss (Ampk; catabolism) and muscle cramp-
ing (Ca2+ influx). We probed our system to gain insight into
whether noncanonical Smo signaling might be responsible for
the side effect in humans. Intriguingly, initial testing revealed
that all compounds except jervine induced contraction in
myocytes (Figure 7F). Because contraction itself induces Ca2+
and Ampk-dependent glucose uptake, this finding precluded
use of myocytes for quantitative determination of the noncanon-
ical arm. We therefore interrogated the canonical antagonists
cyclopamine, jervine, SANT-1, GDC-0449, LDE-225, and XL-
139 and agonists purmorphamine, SAG and the oxysterols
20(s)-OHC and 25-OHC for their noncanonical and canonical
potencies in mature 3T3-L1 adipocytes and Shh-Light2 cells
(Figures 7F and 7G). Insulin, as a glucose uptake positive control,
and Tomatidine, as a steroid-like negative control, were also
tested.
Interestingly, not all Smo modulators induced noncanonical
glucose uptake. Cyclopamine and GDC-0449 did, making
them selective partial agonists, as did SAG and the two oxyster-
ols—thus, dual agonists (Figures 7F, bottom, and S7B–S7D). Of
these, all five elicited significant Ca2+ responses and muscle
contractility (Figure 7F, top). Importantly, however, the reverse
was not true. Not all Ca2+-inducingmodulators elicited a glucose
uptake response (e.g., SANT-1, XL-139, and LDE-225). Thus,
whereas Smo-ligand-induced glucose uptake appears to require
Ca2+ induction, the processes can be pharmacologically un-
coupled. Of note, SANT-1, XL-139, and LDE-225 all block the
initial Smo translocation step to the cilium, suggesting additional
support for the basal-body-dependent mechanism presented
above and consistent with recently proposed multistep activa-tion models of Smo action. Thus, whereas Ca2+ influx is required
for the glucose uptake response, Smo-dependent Ca2+ induc-
tion alone does not induce metabolic rewiring.
Focusing on contractility, all Smo modulators with the excep-
tion of jervine induced Ca2+ influx in the nanomolar range (Fig-
ure 7F). Interestingly, not all canonical agonists induced glucose
uptake. Despite significant Ca2+ and canonical activation signa-
tures, purmorphamine showed no induction of noncanonical
activity. Similarly, jervine showed no induction of any noncanon-
ical response, Ca2+ or glucose. It will be of great interest to see
how Smo ‘‘activation’’ by SAG, cyclopamine, jervine, and pur-
morphamine differ at the protein structure level. Together, these
four compounds can independently uncouple canonical acti-
vation, canonical inhibition, Ca2+ signals, and Ampk signals—
presumably all via the same receptor.
Perhaps most relevant to muscle side effects in humans,
however, the finding that jervine exhibits canonical inhibition
absent of both Ca2+ and glucose uptake responses predicts
that development of small molecule inhibitors minimally impact-
ing muscle contractility is possible. To gauge this hypothesis
in vitro, we have now tested SAG, cyclopamine, GDC-0449,
and jervine in primary human myocytes. Importantly, in keeping
with the 3T3-L1 data, SAG, cyclopamine, and GDC-0449 all
induced robust glucose uptake and P-AMPK responses (Fig-
ures 7H and S7E) in human muscle. They do so in the nanomolar
range, and in keeping with our Ca2+ data, all three compounds
elicit twitching of the human muscle fibers. Again and critically
important, jervine showed no induction of glucose uptake,
Ca2+, or myocyte twitching. Thus, Smo-induced noncanonical
glucose uptake andmuscle contraction are conserved in primary
human muscle cells.
Considering the implications for design of future hedgehog
therapeutics for cancer and other diseases, a rigorous analysis
of the Smo-induced contractile responses appears to be of
immediate and paramount importance.
DISCUSSION
Here, we show that a Smo-dependent noncanonical signal re-
wires metabolism in vitro and in vivo. This Smo-Camkk2-Ampk
axis can be uncoupled from the canonical pathway at the level
of Smo, and cyclopamine and GDC-0449 are selective partial
agonists of this rapid rewiring effect, whereby selective partial
agonists are defined as compounds that are capable of dif-
ferentially regulating two independent pathways via the same
receptor. These demonstrations provide fundamental insights
into Smo signaling, have substantial implications for ongoing
Smo modulator development for cancer, and open the door for
Smo-selective partial agonism as a new therapeutic strategy
for obesity and diabetes.
We previously reported that mice with constitutively active
canonical hedgehog signaling in adipose tissue exhibit a unique
healthy phenotype despite striking white-adipose-specific lipoa-
trophy (Pospisilik et al., 2010). Those findings identified hedge-
hog signaling as one of the first hormonal axes capable of
differentially regulating WAT and BAT adipogenesis. Interest-
ingly, we once again observe BAT selectivity in the in vivo
glucose uptake response to noncanonical agonism. WhatCell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc. 423
distinguishes the responsive tissues (BAT/red muscle) from the
less responsive ones (WAT/white muscle)? Systematic analysis
across more than 25 mouse tissues showed no evidence for
expression-based mechanism of either the canonical or nonca-
nonical hedgehog arms. Several of our own unpublished obser-
vations, however, support the concept that metabolic profile
might determine responsiveness, including a strong TZD depen-
dence of the phenotype and metabolic epistasis that appears to
favor glycolytic metabolic profiles (R.T., J.A.P., and H.E. unpub-
lished data). Certainly critical for the lack of white adipose tissue
responsiveness in vivo, AMPK actually reduces glucose uptake
in this tissue, keeping with its primary role as a storage organ
(Towler and Hardie, 2007).
Indeed, our data reveal a profound role for Smo signaling in
regulating metabolic flux, specificity, and flexibility (Figure 7).
These data are supported by our own transcriptional profiling
of 3T3-L1 cells after 2 days of Shh stimulation that reveal
highly significant enrichment scores for data sets associated
with invasive cancer, hypoxia, and the transcriptional regulator
Hif1a—signatures that clustered around downregulation of the
KEGG/Biocarta pathways oxidative phosphorylation, pyruvate
metabolism, and the TCA cycle, among others (J.A.P. and
H.E., unpublished data). This finding indicates that canonical
signaling reinforces the observed noncanonical metabolic rout-
ing by initiating a transcriptional aerobic glycolysis response
and modulating expression of the entire machinery of primary
metabolism.
Transcriptional reinforcement aside, however, we see Smo-
selective partial agonism doubling whole-body glucose up-
take within 30 min. Also, we observe an apparent parallel
activation of thermogenesis with similar kinetics. The data
therefore raise Smo-selective partial agonism as a therapeutic
option for obesity and types-1 and -2 diabetes. But more funda-
mentally, they demonstrate a dominant physiological response
of noncanonical hedgehog signaling in vivo. What additional
noncanonical responses exist physiologically? Do endogenous
ligands exist that selectively activate either canonical or nonca-
nonical signaling? Certainly the two oxysterols 20(s)OHC and
25OHC are capable. To what extent do these factors underlie
previous ‘‘canonical’’ effects? All of these questions are open.
Many molecules have been shown to stimulate Smo-depen-
dent signaling (Chen et al., 2002b; Corcoran and Scott, 2006;
Nachtergaele et al., 2012; Sinha and Chen, 2006; Wang et al.,
2010). Although screening efforts typically rely on canonical
readouts such as Gli-responsive luciferase reporters, few have
interrogated noncanonical signaling in parallel. Systematic
characterization of selective partial agonism should provide
insights into the biochemical requirements that are necessary
for canonical versus noncanonical stimulation and structural
rationale for design of Smo-selective partial agonists. Based
on what we know, such Smo modulators, much like the very
pleiotropic selective estrogen receptor modulators (SERMs)
(Riggs and Hartmann, 2003), should have the potential to im-
pact multiple Ampk-dependent pathways in and beyond metab-
olism, including cell size (kidney) and immune cell polarity
(macrophages).
The uncoupling of canonical/noncanonical signals and activa-
tion of the Smo-Ampk axis by both SAG and cyclopamine repre-424 Cell 151, 414–426, October 12, 2012 ª2012 Elsevier Inc.sent a paradigm shift. The findings add a new level of complexity
with which a cell can establish downstream signaling diversity
and cell type specificity. Cyclopamine has been shown to inhibit
some noncanonical signals (Chinchilla et al., 2010; Polizio et al.,
2011; Riobo et al., 2006). What distinguishes our findings from
those? First, kinetics. Previous reports have used long-term
measures to assess their effects. Perhaps more likely, however,
is the second messenger system in question and subcellular
localization, for instance, at the cilium.
The last decade of hedgehog research has seen substantial
advances toward unraveling a ‘‘Gli code’’ and linking ligand
binding to transcriptional output (Hui and Angers, 2011; Ruiz i
Altaba et al., 2007). That said, a number of deep-seated para-
digms remain enigmatic: the nature of Gli target specification,
Gli target gene set expansion with signal intensity, and the
inconsistencies in potency of pathway inhibition versus potency
of cancer growth inhibition. The demonstrations that hedge-
hog rewires metabolism and that canonical and noncanonical
paths are independent reveal functional plasticity that may—
at least in part—explain these notions. For instance, metabolic
state alone can drive dramatic cell fate transitions and ex-
pression changes (e.g., immune cell polarity, activation state,
cancer invasiveness, etc.) (Hitosugi et al., 2009; Hsu and Saba-
tini, 2008; Jeon et al., 2012; Shi et al., 2011). Indeed, it will be
intriguing to see to what extent hedgehog’s multiple procancer
effects depend on acute or chronic changes in metabolic state.
We feel that, to properly understand hedgehog phenotype,
future analyses must include secondary messenger repertoire
of the system in question and its respective noncanonical
outputs.
Along similar lines, if canonical and noncanonical arms are
independent, then as long as Smo is expressed, the potential
for a noncanonical response remains. GPCRs have the potential
to signal when internalized (Calebiro et al., 2010); some even
change their downstream effectors accordingly. Oxysterol
binding to Smo has recently been shown to allosterically amplify
hedgehog output (Corcoran and Scott, 2006; Nachtergaele
et al., 2012). We now show that they activate metabolic
rewiring. These cell-permeable lipid derivatives are quantita-
tively dynamic and found throughout the cell, and they respond
to the metabolic milieu. Should the notion of hedgehog respon-
siveness be fine-tuned? Are some hedgehog nonresponsive cell
types still competent for noncanonical signals and metabolic
rewiring? These questions too are now open.
EXPERIMENTAL PROCEDURES
Cell Culture
Primary brown preadipocytes, MEFs, C2C12s, and mouse 3T3-L1 preadipo-
cytes (ATCC) were grown and differentiated as described (Pospisilik et al.,
2010; Todoric et al., 2011; Varjosalo et al., 2006; Wong et al., 2009). Before
stimulations, cells were starved overnight in DMEM containing 1% BSA. All
stimulations were performed in starvation medium. Human myoblast cultures
and myocytes were established from four human study subjects according to
Gaster et al. (2002).
Cellular O2/CO2 Exchange
A Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience) was used
to analyze bioenergetic function of cells. Cellular DNA was measured to adjust
for potential differences in cell densities.
Metabolites
NAD+, NADP+, NADH, NADPH, glucose, and lactate were determined using
commercially available kits (Bioassay Systems). AMP, ADP, and ATP were
determined as described (Liu et al., 2010).
shRNA
Lentiviruses expressing targeting shRNAs were used to transduce cells ac-
cording to standard protocols. Puromycin was used to select stable clones.
Phospho-Protein Enrichment, 2D-PAGE, and Mass Spectrometry
Phosphoproteins of total adipocyte protein were enriched by affinity column
purification, isoelectric focused, and separated by SDS-PAGE. Detection,
matching, background subtraction, normalization, and quantitative compar-
ison of scanned 2D spots used Progenesis SameSpots software (Nonlinear
Dynamics). Spots were excised, tryptic digested, identified, and quantified
using an XCT-Ultra mass spectrometer.
AMPKAR-Foerster Resonance Energy Transfer Assay
Real-time AMPK activation was recorded using the AMPKAR-FRET construct
as described (Tsou et al., 2011).
Ca2+ Signal Measurements
FluoForte AM (Enzo Lifescience) was used to measure dynamic changes of
intracellular calcium levels according to the manufacturer’s instructions.
Glucose Uptake
Basal glucose uptake of human myotubes was determined by capturing
2-[1-14C]-deoxy-glucose (Perkin Elmer) as previously described (Gaster
et al., 2002).
Quantitative RT-PCR Analysis
Total RNA was extracted using TRIzol. cDNA was prepared with the iScript
cDNA Synthesis Kit (Bio-Rad). qPCR was run using intron-spanning and
junction primer pairs on an AbiPRISM 7500fast real-time cycler (Applied Bio-
systems) using the iQ SYBR Green Supermix (Bio-Rad).
Phenotype Microarrays
Phenotype microarray experiments were performed following protocols
provided by Biolog Inc. (http://www.biolog.com/).
Animal Experiments
Eight- to 11-week-old, overnight fasted C57BL/6J male mice were used for
in vivo studies. For cyclopamine testing, mice were injected intraperitoneally
(i.p.) with vehicle (45% HBS) or cyclopamine (10 mg/kg) either alone or in
conjunction with a 1 g/kg OGTT. STZ induction was i.p. (200 mg/kg) followed
by a 72 hr stabilization period. For clamps, femoral catheterized mice were
infused continuously with 1 mg/kg/min somatostatin, and glycemia was
clamped to 12.5 mM by variable infusion of 10% glucose. Mice were main-
tained at steady state for 90 min prior to cyclopamine administration.
Statistical Analysis
Data sets were compared for statistical significance using a two-tailed
Student’s t test, and data are expressed as mean ± SEM unless otherwise
specified. p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
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